-+ 0.00%
-+ 0.00%
-+ 0.00%

REZOLUTE ANNOUNCES PRESENTATION OF PARTICIPANT BASELINE DATA FROM ITS FULLY ENROLLED PHASE 3 STUDY OF ERSODETUG IN CONGENITAL HYPERINSULINISM AT THE UPCOMING ANNUAL MEETING OF THE ENDOCRINE SOCIETY (ENDO 2025)

Reuters·07/09/2025 11:30:00

Please log in to view news